Mohamed Ouizougun-Oubari

Dr. Mohamed Ouizougun-Oubari

Boston University School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JXJin Xie
Jin Xie
MOMohamed Ouizougun-Oubari
Mohamed Ouizougun-Oubari
LWLi Wang
Li Wang
GZGuanglei Zhai
Guanglei Zhai
DWDaitze Wu
Daitze Wu
SCShuai Chen
Shuai Chen
The transcription and replication processes of non-segmented, negative-strand RNA viruses (nsNSVs) are catalyzed by a multi-functional polymerase complex composed of the large protein (L) and a cofactor protein, such as phosphoprotein (P). Previous studies have shown that the nsNSV polymerase can adopt a dimeric form, however, the structure of the dimer and its function are poorly understood. Here we determine a 2.7 Å cryo-EM structure of human parainfluenza virus type 3 (hPIV3) L–P complex with the connector domain (CD′) of a second L built, while reconstruction of the rest of the second L–P obtains a low-resolution map of the ring-like L core region. This study reveals detailed atomic features of nsNSV polymerase active site and distinct conformation of hPIV3 L with a unique β-strand latch. Furthermore, we report the structural basis of L–L dimerization, with CD′ located at the putative template entry of the adjoining L. Disruption of the L–L interface causes a defect in RNA replication that can be overcome by complementation, demonstrating that L dimerization is necessary for hPIV3 genome replication. These findings provide further insight into how nsNSV polymerases perform their functions, and suggest a new avenue for rational drug design.

19 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
SLSébastien Lyonnais
Sébastien Lyonnais
SSS. Kashif Sadiq
S. Kashif Sadiq
CLCristina Lorca-Oró
Cristina Lorca-Oró
LDLaure Dufau
Laure Dufau
SNSara Nieto-Marquez
Sara Nieto-Marquez
GMGilles Mirambeau
Gilles Mirambeau
A growing number of studies indicate that mRNAs and long ncRNAs can affect protein populations by assembling dynamic ribonucleoprotein (RNP) granules. These phase-separated molecular ‘sponges’, stabilized by quinary (transient and weak) interactions, control proteins involved in numerous biological functions. Retroviruses such as HIV-1 form by self-assembly when their genomic RNA (gRNA) traps Gag and GagPol polyprotein precursors. Infectivity requires extracellular budding of the particle followed by maturation, an ordered processing of ∼2400 Gag and ∼120 GagPol by the viral protease (PR). This leads to a condensed gRNA-NCp7 nucleocapsid and a CAp24-self-assembled capsid surrounding the RNP. The choreography by which all of these components dynamically interact during virus maturation is one of the missing milestones to fully depict the HIV life cycle. Here, we describe how HIV-1 has evolved a dynamic RNP granule with successive weak–strong–moderate quinary NC-gRNA networks during the sequential processing of the GagNC domain. We also reveal two palindromic RNA-binding triads on NC, KxxFxxQ and QxxFxxK, that provide quinary NC-gRNA interactions. Consequently, the nucleocapsid complex appears properly aggregated for capsid reassembly and reverse transcription, mandatory processes for viral infectivity. We show that PR is sequestered within this RNP and drives its maturation/condensation within minutes, this process being most effective at the end of budding. We anticipate such findings will stimulate further investigations of quinary interactions and emergent mechanisms in crowded environments throughout the wide and growing array of RNP granules.

10 June 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
AGAxel A. Guzmán-Solís
Axel A. Guzmán-Solís
MOMohamed Ouizougun-Oubari
Mohamed Ouizougun-Oubari
OEOlivier Escaffre
Olivier Escaffre
BLBrendan B. Larsen
Brendan B. Larsen
MLMary Lopez
Mary Lopez
BLBenhur Lee
Benhur Lee
The Nipah and Hendra viruses (NiV and HeV, respectively) are highly pathogenic, with case fatality rates of 40 to 75%, representing substantial public health threats. Although one monoclonal antibody (mAb), mAb102.4, has advanced through phase 1 clinical trials, there remains a critical need for approved therapeutic options against these henipaviruses (HNVs). Development of human mAbs has been constrained by limited access to convalescent patient samples. Here, we describe human mAbs derived from transgenic humanized mice that cross-neutralize extant NiV and HeV strains by binding to their fusion protein (F) or receptor binding protein (RBP). Deep mutational scanning and functional studies demonstrated that the anti-RBP mAb (8G3) targets the receptor binding site and requires multiple simultaneous mutations for escape. Sequence analysis of our anti-F mAbs identified a clonally expanded VH3-33 family with evidence of somatic hypermutation, yielding high-affinity antibodies. Cryo–electron microscopy revealed that our most potent F antibody (2A1) recognizes a conserved quaternary epitope spanning two protomers in trimeric prefusion NiV-F and stabilized, rather than displaced, a key glycan shield, distinguishing it from previously described antibodies targeting this region. The 8G3 and 2A1 mAbs exhibited additive neutralization when combined and provided complete protection against lethal NiV challenge in hamsters when administered individually or as a cocktail, even when treatment was delayed. Using a pseudovirus system, we show that this dual-targeting approach was resilient against a suite of escape mutants compared with monotherapy. Our findings establish a candidate therapeutic strategy that minimizes development of resistance, providing a foundation for next-generation countermeasures against emerging HNVs.

4 April 2026
Verified
Thesis
Closed access
MOMohamed Ouizougun-Oubari
Mohamed Ouizougun-Oubari
Le virus respiratoire syncytial humain (VRS) est responsable de bronchiolites tant chez les nourrisson que chez les personnes âgées. La majorité des nourrissons ont été infectés par le VRS avant l’âge de 2 ans et peut dans certains cas avoir des conséquences fatales. Ce type d’infection respiratoire ne dispose d’aucun traitement efficace à ce jour. Lors de mon arrivée dans l’unité de virologie structurale de l’Institut Pasteur, la structure de la nucléoprotéine N du VRS venait d’être résolue. Disposant de la structure de cette protéine, le premier objectif de cette thèse était de caractériser au niveau structural l’interaction entre cette nucléoprotéine et son principal partenaire viral, la phosphoprotéine P, complexe essentielle au processus de réplication/transcription. A partir de ces données structurales, un second objectif a consisté en la recherche rationnelle d’inhibiteurs ciblant cette interaction en vue du développement de nouvelles molécules thérapeutiques. La première partie de ce manuscrit présente les résultats de la publication de 2015 (Ouizougun-Oubari et al., 2015) présentant un modèle d’étude valide, le N-NTD, permettant d’étudier l’interaction N-P. La structure du complexe NNTD/P2 a permis de caractériser une liste de 100 molécules où une famille moléculaire, les BPdC, sont capables d’inhiber la formation du complexe N-P. La seconde partie du manuscrit décrit les complexes obtenus avec d’autres molécules de la liste de 100 (non-BPdC), ainsi quelques caractérisations biochimiques du caractère inhibiteurs des certains composés. Ensemble, cette étude permet de mettre en lumière une démarche rationnelle en vue d’un développement d’un nouveau type d’inhibiteurs, non seulement chez le VRS, mais à d’autre Mononegavirales, ordre viral incluant de nombreuses maladies émergentes.